Parabolic Drugs Ltd. announced unaudited standalone earnings results for the third quarter and nine months ended December 31, 2015. For the quarter, the standalone company reported net sales of INR 201.3 million against INR 429.0 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 1,516.0 million against INR 202.1 million a year ago. Loss from ordinary activities before tax was INR 1,786.4 million against INR 391.8 million a year ago. Net loss was INR 1,786.4 million against INR 391.8 million a year ago. Basic and diluted loss per share before and after extraordinary items were INR 28.86 against INR 6.33 a year ago.

For the nine months, the standalone company reported net sales of INR 609.9 million against INR 2,021.7 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 2,780.6 million against INR 579.8 million a year ago. Loss from ordinary activities before tax was INR 3,573.5 million against INR 1,137.8 million a year ago. Net loss was INR 3,573.5 million against INR 907.3 million a year ago. Basic and diluted loss per share before and after extraordinary items were INR 57.74 against INR 14.66 a year ago.